Polar Multi-Strategy Master FundTermination Agreement • March 19th, 2024 • AEON Biopharma, Inc. • Pharmaceutical preparations
Re: Agreement (the “Agreement”) by and Among AEON Biopharma, Inc., a Delaware corporation (f/k/a Priveterra Acquisition Corp.), a Delaware corporation (“Counterparty”), AEON Biopharma Sub, Inc. (f/k/a AEON Biopharma, Inc.), a Delaware corporation (“Target”), and Polar Multi-Strategy Master Fund, a Cayman Islands exempted company (“Seller,” “we,” “us,” and “our”), to terminate the Forward Purchase Agreement dated as of June 29, 2023 (the “Forward Purchase Agreement”)
GUARANTYGuaranty • March 19th, 2024 • AEON Biopharma, Inc. • Pharmaceutical preparations • Delaware
This GUARANTY (this “Guaranty”) dated as of March 19, 2024 is made by AEON Biopharma Sub, Inc., a Delaware corporation (“Guarantor”), in favor and for the benefit of Daewoong Pharmaceutical Co., LTD., a company organized and existing under the laws of the Republic of Korea (“Purchaser”).
AEON BIOPHARMA, INC. SENIOR SECURED CONVERTIBLE NOTES DUE 2027 SUBSCRIPTION AGREEMENT March 19, 2024Subscription Agreement • March 19th, 2024 • AEON Biopharma, Inc. • Pharmaceutical preparations • New York
SECURITY AGREEMENTSecurity Agreement • March 19th, 2024 • AEON Biopharma, Inc. • Pharmaceutical preparations • New York
This Security Agreement dated as of March 19, 2024 (this “Agreement”) is made by AEON Biopharma, Inc., a Delaware corporation (“AEON”) and AEON Biopharma Sub, Inc., a Delaware corporation (“AEON Sub” and, together with AEON, the “Debtors” and each a “Debtor”), in favor of Daewoong Pharmaceutical Co., LTD., a company duly organized and existing under the laws of the Republic of Korea (the “Secured Party”).
AEON BIOPHARMA, INC. FOURTH AMENDMENT TO THE LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • March 19th, 2024 • AEON Biopharma, Inc. • Pharmaceutical preparations
This Fourth Amendment to the License and Supply Agreement (this “Fourth Amendment”), is made and entered into as of March 19, 2024 (“Fourth Amendment Effective Date”), by and between AEON Biopharma Sub, Inc. (previously known as AEON Biopharma, Inc.), a Delaware corporation (the “AEON”), and Daewoong Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of the Republic of Korea (“Daewoong”).
